1.Selective COX-2 inhibitor versus nonselective COX-1 and COX-2 inhibitor in the prevention of heterotopic ossification after total hip arthroplasty: a meta-analysis of randomised trials.
Bu-Guo XU ; De-Ting XUE ; Xiang-Hua WANG ; Shi-Gui YAN
China Journal of Orthopaedics and Traumatology 2014;27(7):609-614
OBJECTIVETo evaluate the clinical efficiency of selective cyclo-oxygenase-2 (COX-2) inhibitor compared to traditional nonselective NSAIDs for the prevention of heterotopic ossification (HO) after total hip arthroplasty (THA).
METHODSBy searching Medline, Embase, CENTRAL (Cochrane Central Register of Controlled Trials) and Science Citation Index et al, only randomised controlled studies of selective COX-2 inhibitors VS nonselective COX-1 and COX-2 inhibitors for the prevention of HO after THA were included. The quality assessment of included studies was evaluated according to the standard of the Cochrane Collaboration, and the data were analysised by statistic software Stata 10.0. The HO incidence of both groups in different degrees was compared.
RESULTSFour eligible randomised controlled trials of totally 808 patients were included. Meta-analysis results showed that no statistically significant difference was found in overall incidence of HO (RR = 1.08, 95% CI: 0.71-1.64,P = 0.73), incidence of moderate severe HO (Brooker II and III) (RR = 0.83, 95% CI: 0.48-1.42, P = 0.49) and any grade of Brooker classification between two groups. In all included studies, 16 patients receiving nonselective COX inhibitor (4.4%) discontinued treatment because of gastrointestinal toxicity,whereas 10 patients in the selective COX-2 inhibitor group (2.7%) discontinued for gastrointestinal side effects.
CONCLUSIONThe selective COX-2 inhibitors are as equally effective as nonselective NSAIDs for the prevention of HO after THA. Considering the side effects of nonselective NSAIDs, selective COX-2 inhibitors were recommend for the prevention of HO after THA.
Anti-Inflammatory Agents, Non-Steroidal ; adverse effects ; therapeutic use ; Arthroplasty, Replacement, Hip ; adverse effects ; Cyclooxygenase 2 Inhibitors ; adverse effects ; therapeutic use ; Cyclooxygenase Inhibitors ; adverse effects ; therapeutic use ; Humans ; Ossification, Heterotopic ; prevention & control ; Randomized Controlled Trials as Topic
2.Innovation of anti-inflammatory drugs--inhibition of cyclooxygenases.
Acta Pharmaceutica Sinica 2005;40(11):967-969
Anti-Inflammatory Agents, Non-Steroidal
;
adverse effects
;
pharmacology
;
Cardiovascular Diseases
;
chemically induced
;
Celecoxib
;
Cyclooxygenase 1
;
metabolism
;
Cyclooxygenase 2
;
metabolism
;
Cyclooxygenase 2 Inhibitors
;
adverse effects
;
pharmacology
;
Epoprostenol
;
biosynthesis
;
Humans
;
Lactones
;
adverse effects
;
pharmacology
;
Pyrazoles
;
adverse effects
;
pharmacology
;
Sulfonamides
;
adverse effects
;
pharmacology
;
Sulfones
;
adverse effects
;
pharmacology
;
Thromboxane A2
;
metabolism
3.Aspirin inhibits the proliferation of tobacco-related esophageal squamous carcinomas cell lines through cyclooxygenase 2 pathway.
Qiao-zhi ZHOU ; Hai-bo LIU ; Xin-chun DING ; Peng LI ; Shu-tian ZHANG ; Zhong-lin YU
Chinese Medical Journal 2007;120(23):2086-2091
BACKGROUNDCigarette smoking has been verified as the risk factor of esophageal squamous cell carcinoma (ESCC). Overexpression of cyclooxygenase 2 (COX-2) is shown in ESCC. The objective of this study was to investigate the effects of cigarette smoking ethanol extract (EE) on the proliferation of the human ESCC cell lines, and to explore the correlation between the proliferation rate of human ESCC cell lines and the expression pattern of COX-2. Whether aspirin can inhibit the proliferation of the ESCC cell lines pretreated with EE, and regulate the mRNA expression levels of COX-2 are also examined.
METHODSTwo human ESCC cell lines were selected. EC109 was poorly differentiated and EC9706 was highly differentiated. EC109 and EC9706 were treated with EE and aspirin for different time course. The cell growth of ESCC was measured by MTT reduction assay and the expression of COX-2 was measured by RT-PCR and Western blot analysis.
RESULTSEE promoted the proliferation of EC109 and EC9706 in dose- and time-dependent manners. In the concentration range (10 - 100 microg/ml for EE) and in the time range (24 - 72 hours) after addition of EE, the cell proliferation was prominent in an up-scaled manner respectively. Aspirin could inhibit the proliferation of cell lines EC109 and EC9706, pretreated with EE for 5 hours, in a dose-dependent manner. In the concentration range (0.5 - 8.0 mmol/L for aspirin), the cell growth inhibition was prominent in an up-scaled manner accordingly (P < 0.05). The effect of EE on cell proliferation was correlated with the up-regulation of COX-2 gene. However, the cell growth inhibition of aspirin was correlated with the down-regulation of COX-2 gene.
CONCLUSIONSEE can stimulate the proliferation of human ESCC cell lines EC109 and EC9706, most likely through up-regulating the expression of COX-2. Aspirin can inhibit the proliferation of ESCC cell lines induced by EE, which suggests it may be advantageous in the chemoprevention and therapy of human tobacco-related ESCC. And its effect is likely to be related with modulating COX-2 activity.
Aspirin ; pharmacology ; Carcinoma, Squamous Cell ; drug therapy ; etiology ; pathology ; Cell Line, Tumor ; Cell Proliferation ; drug effects ; Cyclooxygenase 2 ; physiology ; Cyclooxygenase 2 Inhibitors ; pharmacology ; Esophageal Neoplasms ; drug therapy ; etiology ; pathology ; Humans ; Smoking ; adverse effects
4.Effect of celecoxib on pulmonary hypertension of chronic hypoxia and hypercapnic rats.
Hai-Huan ZENG ; Ling-Jie LIU ; Yu-Ping HUANG ; Yu-Peng XIE ; Liang-Xing WANG
Chinese Journal of Applied Physiology 2011;27(1):29-32
OBJECTIVETo study the effect of celecoxib on chronic hypoxia and hypercapnic pulmonary hypertension.
METHODSSD rats were randomly divided into normal control group (A), hypoxic hypercapnic group (B), hypoxic hypercapnia+ celecoxib group (C). The content of TXB2 and 6-keto-PGF1alpha in plasma and lung were detected by the technique of radioimmunology.
RESULTS(1) Mean pulmonary arteria pressure(mPAP) was significantly higher in rats of B group than those of A group. mPAP was significantly higher in rats of C group than those of B group. Differences of mPAP were not significant in three groups. (2) The content of TXB2 in plasma and lung and the ratio of TXB2/6-keto-PGF1alpha were significantly higher in rats of B group than those of A group. The ratio of TXB2/6-keto-PGF1alpha was significantly higher and the content of 6-keto-PGF1alpha in plasma and lung was significantly lower in rats of C group than those of B group. (3) Light microscopy showed that WA/TA (vessel wall area/total area) and PAMT (the thickness of medial smooth cell layer) were significantly higher in rats of B group than those of A group. WA/TA and PAMT were significantly higher in rats of C group than those of B group. (4) Electron microscopy showed the thickening of vessel wall and the proliferation of collagen fiber in B group and augmentation of smooth muscle cell and abundance of myofilament in pulmonary arterioles in C group.
CONCLUSIONCelecoxib can aggravate hypoxic hypercapnia pulmonary hypertension and pulmonary vessel remodeling by increasing the ratio of TXA2/PGI2.
Animals ; Celecoxib ; Chronic Disease ; Cyclooxygenase 2 Inhibitors ; adverse effects ; pharmacology ; Epoprostenol ; blood ; Hypercapnia ; complications ; Hypertension, Pulmonary ; etiology ; physiopathology ; Hypoxia ; complications ; Male ; Pyrazoles ; adverse effects ; pharmacology ; Rats ; Rats, Sprague-Dawley ; Sulfonamides ; adverse effects ; pharmacology ; Thromboxane A2 ; blood
5.Comparative Study of the Safety and Effectiveness of Tramadol 37.5 mg/Acetaminophen 325 mg Combined Tablets and Cyclo-Oxygenase-2 (Celecoxib) Inhibitor for the Treatment of Chronic Low Back Pain: A Multicenter, Randomized, Comparative Clinical Study.
Chang Hoon JEON ; Dong Jae KIM ; Dong Jun KIM ; Hwan Mo LEE ; Heui Jeon PARK ; Hak Sun KIM ; Dong Eun SHIN ; Han Ter MIN
Journal of Korean Society of Spine Surgery 2005;12(4):299-309
STUDY DESIGN: This is a multicenter, randomized comparative outpatient study on a 8-week administration of Tramadol 37.5 mg/Acetaminophen and 325 mg (Tramadol/APAP) combination tablets and Cyclo-Oxygenase-2 inhibitor (Celecoxib). OBJECTIVES: We wanted to evaluate the efficacy and safety of Tramadol/APAP combination tablets and Celecoxib for the treatment of chronic low back pain. SUMMARY OF THE LITERATURE REVIEW: Tramadol/APAP combination tablets have an analgesic efficacy for the treatment of chronic low back pain. The conditions for which COX-2 inhibitors were be used included a variety of musculoskeletal conditions. However, further analyses are needed to determine the efficacy and safety of Tramadol/APAP combination tablets and Celecoxib for the treatment of chronic low back pain. MATERIALS AND METHODS: One hundred twenty-five patients with chronic low back pain (pain visual analogue scale [VAS] scores >40 mm on 100 mm scale) were randomized to take the Tramadol/APAP combination tablets or Celecoxib for 8 weeks. The primary outcome measure was the pain VAS score, pain relief score and the Korean-version of Oswestry Disability Index (KODI). RESULTS: The study enrolled 125 patients (56 in the Tramadol/APAP tablets group and 69 in the Celecoxib group). There were no significant differences between Tramadol/APAP combination tablets and Celecoxib with regard to the pain VAS scores (VAS; 27.99+/-21.22 vs 24.56+/-16.58, respectively, p>0.05), the pain relief score and the mean decreased disability score on the KODI (0.42+/-0.59 vs 0.46+/-0.05, respectively). The adverse drug reactions showed a statistically significant difference (p<0.05). CONCLUSIONS: The results of this study suggest that Tramadol/APAP combination tablets are just as effective as celecoxib for relieving chronic low back pain.
Cyclooxygenase 2 Inhibitors
;
Drug-Related Side Effects and Adverse Reactions
;
Humans
;
Low Back Pain*
;
Outcome Assessment (Health Care)
;
Outpatients
;
Tablets*
;
Tramadol*
;
Celecoxib
6.Prescription Pattern of NSAIDs and the Prevalence of NSAID-induced Gastrointestinal Risk Factors of Orthopaedic Patients in Clinical Practice in Korea.
Sung Hun LEE ; Chang Dong HAN ; Ick Hwan YANG ; Chul Won HA
Journal of Korean Medical Science 2011;26(4):561-567
This is a cross-sectional observational study undertaken to explore the current prescription pattern of non-steroidal anti-inflammatory drugs (NSAIDs) and the prevalence of NSAID-induced gastrointestinal (GI) risk factors of orthopaedic patients in real clinical practice in Korea. Study cohort included 3,140 orthopaedic outpatients at 131 hospitals and clinics between January 2008 and August 2008. A self-administered questionnaire was completed by each patient and physician. A simplified risk scoring scale (the Standardized Calculator of Risk for Events; SCORE) was used to measure patients' risk for GI complications. The pattern of NSAIDs prescription was identified from medical recordings. Forty-five percents of the patients belonged to high risk or very high risk groups for GI complications. The cyclooxygenase-2 enzyme (COX-2) selective NSAID showed a propensity to be prescribed more commonly for high/very high GI risk groups, but the rate was still as low as 51%. In conclusion, physician's considerate prescription of NSAIDs with well-understanding of each patient's GI risk factors is strongly encouraged in order to maximize cost effectiveness and to prevent serious GI complications in Korea. Other strategic efforts such as medical association-led education programs and application of Korean electronic SCORE system to hospital order communication system (OCS) should also be accompanied in a way to promote physician's attention.
Adult
;
Aged
;
Aged, 80 and over
;
Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
;
Cohort Studies
;
Cross-Sectional Studies
;
Cyclooxygenase 2/metabolism
;
Cyclooxygenase 2 Inhibitors/adverse effects
;
Drug Prescriptions
;
Female
;
Gastrointestinal Diseases/chemically induced/complications/*epidemiology
;
Humans
;
Male
;
Middle Aged
;
Musculoskeletal Diseases/complications/*drug therapy
;
Prevalence
;
Questionnaires
;
Republic of Korea
;
Risk Factors
7.Guidelines of Prevention and Treatment for NSAID-related Peptic Ulcers.
Jun Haeng LEE ; Yong Chan LEE ; Seong Woo JEON ; Jeong Wook KIM ; Sang Woo LEE
The Korean Journal of Gastroenterology 2009;54(5):309-317
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used medications in Korea. Gastrointestinal toxicity, including peptic ulcer, is a common adverse effect of NSAIDs. Risk factors for NSAID-related peptic ulcer include a previous history of peptic ulcer, advanced age, high dose, concomitant use of corticosteroids, anticoagulants, other NSAIDs including low-dose aspirin. Preventive measure(s), such as COX-2 inhibitor, proton pump inhibitor or misoprostrol, should be done for patients requiring NSAID therapy who have high-risk factor(s) for peptic ulcer. Low dose aspirin also increases the risk of peptic ulcer, so preventive measure(s) should be done for high-risk patients. The eradication of Helicobacter pylori is recommended for high-risk NSAID-users. Treatment strategies for peptic ulcers in NSAID users are mostly the same for peptic ulcers in NSAID non-users.
Anti-Inflammatory Agents, Non-Steroidal/*adverse effects
;
Anti-Ulcer Agents/therapeutic use
;
Anticoagulants/adverse effects
;
Aspirin/*adverse effects
;
Cyclooxygenase 2 Inhibitors/therapeutic use
;
Helicobacter Infections/diagnosis/drug therapy
;
Helicobacter pylori
;
Humans
;
Misoprostol/therapeutic use
;
Peptic Ulcer/drug therapy/prevention & control/*therapy
;
Proton Pump Inhibitors/therapeutic use
8.Discussion of anti-inflammatory mechanism of cyclooxygenase (COX-2) inhibitor in improving cardiovascular safety.
Jin-Long MAO ; Xiao-Yu LI ; Rong SUN
China Journal of Chinese Materia Medica 2014;39(20):4054-4059
The new generation cyclooxygenase (COX-2) inhibitor could reduce the gastrointestinal side effect of NSAID drugs, but eventually increase the cardiovascular risk, because its selective inhibition of COX-2 induces the imbalance between PGI2 and TXA2 and the reduction of vasodilatory NO. Under pathological conditions, active oxygen species (O2-*2, etc) were used to induce endo- thelial dysfunction, activate NF-κB to induce expressions of pro-inflammatory cytokines IL-1β and TNF-α, increase ET-1, TXA2 with vasoconstrictor effect, reduce PGI2 and NO with vasodilatory effect, generate further oxidative damage together with NO, and reduce the bioavailability of NO. NO-NSAIDs and NO-Coxibs drugs raised the level of NO by introducing NO-donor (ONO2). NSAIDs drugs enhanced the anti-inflammatory activity of COX-2 and reduced gastrointestinal side effects by inhibiting selectively COX-2. If antioxidant structures with active ingredients of traditional Chinese medicines were introduced to improve the antioxidant activity of NSAIDs, they could scavenge the active oxygen species to protect the normal function of vascular endothelia and enhance the bioavailability of NO, which is conducive to enhance the cardiovascular safety of cyclooxygenase (COX-2) inhibitor.
Anti-Inflammatory Agents
;
therapeutic use
;
Biomarkers, Pharmacological
;
Cardiovascular Diseases
;
drug therapy
;
enzymology
;
immunology
;
Cyclooxygenase 2
;
immunology
;
Cyclooxygenase 2 Inhibitors
;
adverse effects
;
therapeutic use
;
Drugs, Chinese Herbal
;
therapeutic use
;
Humans
;
NF-kappa B
;
immunology
;
Reactive Oxygen Species
;
immunology
;
Tumor Necrosis Factor-alpha
;
immunology
9.Study on the mechanism of preventing alcholic liver disease by selective cyclooxygenase 2 inhibitor.
Jun-ying ZHOU ; Dong-fang ZHOU ; Ying-hui LIU ; Wei WANG ; Feng WEI
Chinese Journal of Hepatology 2009;17(7):559-560
Animals
;
Celecoxib
;
Cyclooxygenase 1
;
genetics
;
metabolism
;
Cyclooxygenase 2
;
genetics
;
metabolism
;
Cyclooxygenase 2 Inhibitors
;
pharmacology
;
therapeutic use
;
Cytokines
;
metabolism
;
Disease Models, Animal
;
Ethanol
;
adverse effects
;
Fatty Liver, Alcoholic
;
pathology
;
prevention & control
;
Immunohistochemistry
;
Liver
;
drug effects
;
metabolism
;
pathology
;
Liver Cirrhosis, Alcoholic
;
pathology
;
prevention & control
;
Liver Diseases, Alcoholic
;
pathology
;
prevention & control
;
Pyrazoles
;
pharmacology
;
therapeutic use
;
RNA, Messenger
;
genetics
;
metabolism
;
Rats
;
Reverse Transcriptase Polymerase Chain Reaction
;
Sulfonamides
;
pharmacology
;
therapeutic use
10.NF-kappaB Binding Activity and Cyclooxygenase-2 Expression in Persistent betaCCI(4)-Treated Rat Liver Injury.
Sang Hyun KIM ; Hyung Jun CHU ; Dae Hwan KANG ; Geun Am SONG ; Mong CHO ; Ung Suk YANG ; Hyon Jeen KIM ; Hae Young CHUNG
Journal of Korean Medical Science 2002;17(2):193-200
The involvement of NF-kappaB binding activity is known to be important in the mechanism of acute liver injury and in the induction of cyclooxygenase (COX-2). This study was performed to evaluate NF-kappaB binding activity and the expression of COX-2 in chronic liver injury induced by carbon tetrachloride (betaCCI(4)). Liver tissues from Sprague - Dawley rats were collected at 1, 3, 5, and 7th week after intraperitoneal injection of 0.1 mL of betaCCI(4)/100 g body weight twice a week. Reactive oxy-gen species (ROS) were measured in the postmitochondrial fraction by dichlorofluorescein formation with a fluorescent probe. An electrophoretic mobility shift assay was performed for NF-kappaB binding activity. Western blot was performed to measure the level of COX-1, COX-2, p65, p50, and I B proteins. ROS and NF-kappaB activity increased during the CCl4-induced chronic liver injury. The expression of nuclear p65 protein and p50 protein increased compared with that of the control, while the cytoplasmic I B protein decreased as the inflammation persisted. The expression of COX-2 in betaCCI(4)-treated rat liver increased compared with that of the control. It could be suggested that ROS produced by betaCCI(4) treatment increased NF-kappaB binding activity and thereby COX-2 expression, and these might be implicated in the progress of chronic liver damage.
Animals
;
Biological Transport
;
Carbon Tetrachloride/administration & dosage/*adverse effects
;
Carbon Tetrachloride Poisoning/*metabolism/pathology
;
Cell Nucleus/metabolism
;
Cyclooxygenase 1
;
Cyclooxygenase 2
;
Cytoplasm/metabolism
;
I-kappa B Proteins/biosynthesis
;
Isoenzymes/*biosynthesis
;
Liver/drug effects/*injuries/pathology
;
Membrane Proteins
;
NF-kappa B/antagonists & inhibitors/*metabolism
;
NF-kappa B p50 Subunit
;
Prostaglandin-Endoperoxide Synthases/*biosynthesis
;
Protein Binding
;
Rats
;
Rats, Sprague-Dawley
;
Reactive Oxygen Species
;
Transcription Factor RelA